FDA Approves Marnetegragene Autotemcel for Severe LAD-I in Pediatrics

Executive Brief

News Report

The News: FDA approves marnetegragene autotemcel for pediatric severe LAD-I.
Clinical Win: This gene therapy offers a new treatment option for a rare and severe condition.
Target Specialty: pediatric hematology, immunology

Key Data at a Glance

Approval Date: March 26, 2026
Condition: Severe Leukocyte Adhesion Deficiency Type I
Manufacturer: Rocket Pharmaceuticals, Inc.

The FDA approved marnetegragene autotemcel (Kresladi) for the treatment of pediatric patients with severe leukocyte adhesion deficiency type I (LAD-I) on March 26, 2026. This marks a significant advancement in gene therapy for a rare and life-threatening condition, providing new hope for affected families.

Clinical Context

Severe leukocyte adhesion deficiency type I (LAD-I) is a rare genetic disorder caused by mutations in the ITGB2 gene, which impairs the ability of white blood cells to adhere to blood vessel walls and migrate to sites of infection. This deficiency leads to recurrent, severe bacterial and fungal infections, often resulting in significant morbidity and mortality during childhood. Current treatment options are limited, primarily involving allogeneic hematopoietic stem cell transplantation, which carries high risks, especially in patients without an HLA-matched sibling donor. The approval of Kresladi represents a novel therapeutic approach, utilizing the patient's own genetically modified hematopoietic stem cells to restore immune function by introducing functional copies of the ITGB2 gene. This therapy aims to significantly improve the quality of life and survival rates for pediatric patients suffering from this debilitating condition.

Key Findings

The FDA approved Kresladi (marnetegragene autotemcel) for pediatric patients with severe leukocyte adhesion deficiency type I (LAD-I) due to biallelic variants in ITGB2 without an available HLA-matched sibling donor for allogeneic hematopoietic stem cell transplant [1].

The therapy involves the genetic modification of the patient’s own hematopoietic stem cells to express the ITGB2 gene, which is crucial for proper immune function [2].

The safety and efficacy of Kresladi were evaluated in a multicenter, open-label study, demonstrating significant increases in neutrophil CD18 and CD11a cell surface expression, indicative of improved immune activity, sustained through 24 months post-infusion [1].

Safety & Tolerability

The most common adverse events reported included anemia, low platelet and white blood cell counts, and infections, highlighting the need for careful monitoring post-treatment [1].

What This Means for Clinical Practice

The approval of Kresladi provides a new treatment option for pediatric patients with severe LAD-I, addressing a critical unmet need in this vulnerable population. Clinicians should consider this therapy as a viable alternative for patients who lack suitable donors for stem cell transplantation. The gene therapy approach not only aims to improve immune function but also reduces the risks associated with traditional transplant methods. As Kresladi becomes available, healthcare providers will need to establish protocols for patient selection, monitoring for adverse effects, and long-term follow-up to assess the therapy's impact on patient outcomes. This advancement underscores the importance of personalized medicine and gene therapy in treating rare genetic disorders.

Clinical Perspective

Workflow: Clinicians will need to adapt their workflows to incorporate genetic testing and patient selection for Kresladi.

Economics: The introduction of this therapy may impact healthcare costs related to managing severe LAD-I, potentially reducing hospitalization rates.

Patient Outcomes: Improved immune function from Kresladi could lead to better long-term health outcomes for pediatric patients with LAD-I.

Editorial Team, Rare Disease

FDA Approves Marnetegragene Autotemcel for Severe LAD-I in Pediatrics

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Rare Disease in your inbox.

Related Drug Updates

FDA Approves Tividenofusp Alfa for Hunter Syndrome: First Neurologic Treatment in 20 Years

FDA Approves Tividenofusp Alfa for Hunter Syndrome: First Enzyme Replacement Therapy for Neurologic Symptoms

FDA Approves Doxecitine and Doxribtimine for Thymidine Kinase 2 Deficiency: Over 90% Survival Benefit

Verified HCP Portal